News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,569 Results
Type
Article (87434)
Company Profile (739)
Press Release (770379)
Multimedia
Podcasts (198)
Webinars (29)
Section
Business (232774)
Career Advice (4144)
Deals (39875)
Drug Delivery (144)
Drug Development (91185)
Employer Resources (205)
FDA (18257)
Job Trends (17425)
News (396870)
Policy (39845)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (124)
Alliances (56794)
ALS (155)
Alzheimer's disease (1755)
Antibody-drug conjugate (ADC) (314)
Approvals (18370)
Artificial intelligence (475)
Autoimmune disease (163)
Automation (32)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (205)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (540)
Cancer (4295)
Cardiovascular disease (302)
Career advice (3568)
Career pathing (41)
CAR-T (294)
CDC (36)
Celiac Disease (1)
Cell therapy (771)
Cervical cancer (29)
Clinical research (76153)
Collaboration (1624)
Company closure (4)
Compensation (1002)
Complete response letters (65)
COVID-19 (2928)
CRISPR (85)
C-suite (750)
Cystic fibrosis (143)
Data (5448)
Decentralized trials (2)
Denatured (73)
Depression (115)
Diabetes (344)
Diagnostics (6984)
Digital health (25)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (260)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (202)
Earnings (98037)
Editorial (57)
Employer branding (25)
Employer resources (174)
Events (132856)
Executive appointments (833)
FDA (20640)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1283)
Gene editing (184)
Generative AI (47)
Gene therapy (610)
GLP-1 (934)
Government (5327)
Grass and pollen (4)
Guidances (276)
Healthcare (20779)
HIV (45)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (270)
Immuno-oncology (61)
Indications (85)
Infectious disease (3151)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (98)
Intellectual property (200)
Interviews (816)
IPO (17811)
IRA (45)
Job creations (5199)
Job search strategy (2866)
JPM (67)
Kidney cancer (16)
Labor market (93)
Layoffs (640)
Leadership (37)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (588)
Lymphoma (333)
Machine learning (41)
Management (66)
Manufacturing (727)
MASH (161)
Medical device (14425)
Medtech (14455)
Mergers & acquisitions (22751)
Metabolic disorders (1075)
Multiple sclerosis (154)
NASH (22)
Neurodegenerative disease (333)
Neuropsychiatric disorders (80)
Neuroscience (2911)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5080)
Now hiring (67)
Obesity (526)
Opinion (326)
Ovarian cancer (152)
Pain (153)
Pancreatic cancer (171)
Parkinson's disease (260)
Partnered (33)
Patents (397)
Patient recruitment (425)
Peanut (57)
People (66307)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23609)
Phase 2 (33145)
Phase 3 (24822)
Pipeline (4387)
Policy (283)
Postmarket research (3544)
Preclinical (10591)
Press Release (72)
Prostate cancer (205)
Psychedelics (52)
Radiopharmaceuticals (280)
Rare diseases (805)
Real estate (7423)
Recruiting (81)
Regulatory (28261)
Reports (63)
Research institute (2696)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (226)
Series B (166)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4325)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (123)
Vaccines (1008)
Venture capital (92)
Weight loss (341)
Women's health (73)
Worklife (22)
Date
Today (106)
Last 7 days (527)
Last 30 days (1816)
Last 365 days (25389)
2026 (2676)
2025 (25543)
2024 (34032)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (289)
Arkansas (8)
Asia (51140)
Australia (9003)
California (9780)
Canada (2490)
China (1066)
Colorado (307)
Connecticut (391)
Delaware (296)
Europe (116948)
Florida (1266)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (654)
India (58)
Indiana (450)
Iowa (21)
Japan (344)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1262)
Massachusetts (7359)
Michigan (244)
Minnesota (453)
Mississippi (5)
Missouri (79)
Montana (29)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2569)
New Mexico (29)
New York (2563)
North Carolina (1424)
North Dakota (9)
Northern California (4805)
Ohio (258)
Oklahoma (18)
Oregon (51)
Pennsylvania (1883)
Puerto Rico (23)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3775)
Tennessee (60)
Texas (1372)
United States (33993)
Utah (210)
Vermont (1)
Virginia (170)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (83)
858,569 Results for "korro bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
·
3 min read
·
Dan Samorodnitsky
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.
November 13, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Korro to Host Virtual Analyst Day on January 27, 2026
January 20, 2026
·
8 min read
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.
February 2, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
·
1 min read
Press Releases
Korro to Participate in Upcoming Investor and Scientific Conferences
September 3, 2025
·
2 min read
Press Releases
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
November 13, 2025
·
15 min read
Press Releases
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
·
12 min read
Genetown
Korro to Participate in Upcoming June Investor and Scientific Conferences
Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences.
May 30, 2024
·
2 min read
Press Releases
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
July 22, 2025
·
7 min read
1 of 85,857
Next
